Title: A Cross Sectional Study Characerization and Antimicrobial Susceptibility Pattern of Clinical Isolates of Acinetobacter at a Tertiary Health Care Teaching Hospital, Bhavnagar, Gujarat
Authors: Dr Chirag N. Ghoghari, Dr Kairavi J. Desai, M.B.B.S., M.D.
DOI: https://dx.doi.org/10.18535/jmscr/v5i6.209
Abstract
Introduction: Acinetobacter is considered an important nosocomial pathogen because of its intrinsic as well as acquired antibiotic resistance. Hospital acquired infection is most common. The genus Acinetobacter consists of Gram negative, facultative aerobic organisms that are ovoid in shape and may appear as gram negative cocco-bacilli. This study conducted in a tertiary care centre from August 2014 to March 2016.
Material and Method: Sample like blood pus and other body fluid are collected from 72 patients into wide mouth open sterile container. Samples processed by microscopy by wet mount and gram stain. Samples cultured on Mac Conkey and Blood Agar media by standard loop method for semi-quantitative culture and incubated aerobically for 24 hrs at 37°C.Antibiotic sensitivity testing by Kirby Bauer method according to CLSI guidelines.
Result: All 72 cases observed more commonly in patients with hospital admitted patients. Bacteria isolated included A.baumanii with a prevalence of 88.88%, followed by A. Lwoffii spp 11.11% were also isolated.
Conclusion: Risk factor associated with nosocomial infections are associated with duration of hospital stay, more common among patients with catheterization and Mechanical ventilation, Surgical site infection subjects. Further, long term studies investigating the occurrence of complications in patients with XDR and PDR studies for studying the efficacy of antimicrobial therapy in preventing further complications in patients with Hospital acquired infections.
Keyword: Acinetobacter Baumanii, Acinetobacter Lwoffii, CLSI- Clinical laboratory standard institute. XDR – Extended Drug Resistance. PDR- Pan Drug resistance.
References
1. Bonomo RA ,Szabo D.;Mechanism of Multidrug Resistence in Acinetobacter Species and pseudomonas aeruginosa.Clin Inf Dis2006 ;43:49-56
2. Cisneros JM,Reyes JM,,Pachon J,Beceril B,Cabarello FJ,Garcia-Garmendia JL,At al Bacteremia due to A. Baumannii Epidemiology,Clinical Findings and prognostic features. aeruginosa.Clin Inf Dis:1996:22:1026-1032.
3. David M Allen,Barry J.Hartman,Chapter 219.In : Mandell,Douglas & Bennett’s principle & practice of Infectious disease 6th edition .Editors:Gerald mandell,John Benett:2005,2,2632-2635.
4. Anathnarayan & Textbook of Microbiology 9th Edition :page 397-398
5. Topley & wilson’s Textbook of Microbiology Diseases. New York: Churchill Livingstone 875-905, 2006.
6. Mackie & McCartney Clinical microbiology, 14th edition:14page no: 294.
7. District-Laboratory-Practice-in-Tropical-CountriesPart-2, Monica-Cheesbrough chapter 7.12
8. Collier L, Balow A, Sussman M, Duerden BI. Topley and Wilson’s Microbiology and microbial infections. 9th ed. System-atic Bacteriology. Vol. 2, London: Arnold; 969-95
9. Koneman’s Color Atlas and textbook of diagnostic microbiology, 5th edition, chapter 5;page no 286-288.
10. Bailey Scott Diagnostic Microbiology, 13th edition, Page no 245
11. CLSI guideline 2012, page no 126-142.
12. Koneman’s Color Atlas and textbook of diagnostic microbiology, 5th edition, chapter 5 page 294 on table no 5.
13. Harrison’s Principle of Internal Medicine, 19th edition, part 8, Section 2, Chapter 162, page 861
14. Bailey Scott Diagnostic Microbiology, 13th edition, Chapter 73, Page no 921
15. Jawetz, Melnick, & Adelberg's Medical Microbiology 24th edition chapter 9.
16. Allen K.D., Green H. T. (1987). Hospital outbreak of multi-resistant Acinetobacter anitratus: an airborne mode of spread? Journal of Hospital Infection (9), 110-119.
17. Anstey N. M., Currie. B. J., Withnall K. M. (1992). Community-Acquired Acinetobacter Pneumonia in the Northern Territory of Australia. Clinical Infectious Diseases, 14(1), 83-91.
18. Arroyo L.A., Mateos. I., Gonzalez V., Aznar J. (2009). In Vitro Activities of Tigecycline, Minocycline, and Colistin-Tigecycline Combination against Multi- and Pandrug-Resistant Clinical Isolates of Acinetobacter baumannii Group. Antim-icrobial Agents Chemotherapy, 53(3), 1295-1296.
19. Berenbaum M.C. (1978). A Method for Testing for Synergy with Any Number of Agents Journal of Infectious Diseases, 137(2), 122-130.
20. Bergogne-Berezin E., Towner K.J. (1996). Acinetobacter spp. as Nosocomial Pathogens: Microbiological, Clinical, and Epidemiological Features. Clinical Microbiological Reviews,148-165.
21. Berlau J., Aucken. H. M., Houang E., Pitt T.L. (1999). Isolation of Acinetob-acter spp. including A. baumannii from vegetables: implications for hospital-acquired infections. Journal of Hospital Infection, 42, 201-204.
22. Bonapace C.R., White. R. L., Friedrich L.V., Bosso J.A. (2000). Evaluation of antibiotic synergy against Acinetobacter baumannii: a comparison with Etest, time-kill, and checkerboard methods. Diagnostic Microbiology and Infectious Disease 38, 43-50.
23. Chen H., Lai C., Chan Y. & other authors (2005). Clinical significance of Acinetobacter species isolated from cerebrospinal fluid. Scandinavian Journal of Infectious Diseases, 37, 669-675.
24. Cisneros J.M., Rodrıguez-Bano J. (2002). Nosocomial bacteremia due to Acineto-bacter baumannii: epidemiology, clinical features and treatment. Clinical Micro-biology and Infection, 8(11), 687–693.
25. Cisneros J.M., Reyes. M. J., Pachón J., & other authors (1996). Bacteremia due to Acinetobacter baumannii: epidemiology, clinical findings, and prognostic features. Clinical Infectious Diseases, 22(6), 1026-1032.
26. CLSI. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria that grow aerobically; Approved Standard - Seventh Edition. CLSI document M7-A7. Wayne, PA. Clinical Laboratory Standards Institute; 2006.
27. CLSI. Performance Standard for antimi-crobial susceptibility testing; Twentieth informational supplement. CLSI docu-ment M100-S20. Wayne, PA: Clinical Laboratory Standards Institute; 2010.
28. Corrigan K.M., Harmis N. Y., Willcox M.D.P. (2001.). Association of Acinet-obacter species with contact lens–induced adverse responses. Cornea, 20(5),463-466.
29. Dijkshoorn L, Nemec A., Seifert H. (2007). An increasing threat in hospitals: multidrug-resistantAcinetobacter baum-annii. Nature reviews: Microbiology, 5,
30. Eliopoulos G.M., Moellering R.C., Jr. (1982). Antibiotic synergism and antimicrobial combinations in clinical infections Reviews of Infectious Diseases, 4(2), 282-293.
31. Fagon J., Chastre J., Hance A.J., & other authors. (1993). Nosocomial pneumonia in ventilated patients: A cohort study evaluating attributable mortality and hospital stay. American Journal of Medicine 94, 281-288.
32. Falagas M. E., Karveli E. A., Kelesi-dis I. and Kelesidis T. (2007). Com-munity-acquired Acinetobacter infections Eur J Clin Microbiol InfectDis26,857-868.
33. Fournier P.E., Richet. H. (2006). The epidemiology and control of Acinetobacter baumannii in health care facilities Clinical Infectious Diseases 42, 692-699.
34. Garnacho-Montero J., Ortiz-Leyba C., Herrera-Melero I., & other authors. (2008). Mortality and morbidity attributable to inadequate empirical antimicrobial therapy in patients admitted to the ICU with sepsis: a matched cohort study Journal of Antimicrobial Chemotherapy 61, 436-441.
35. Gaynes R., Edwards J. R. (2005). Overview of nosocomial infections caused by Gram-negative bacilli. Clinical Infectious Diseases 41, 848-854.
36. Getchell-White S.I., Donowitz L. G., Gröschel D.H.M. (1989). The inanimate environment of an intensive care unit as a potential source of nosocomial bacteria: evidence for long survival of Acineto-bacter calcoaceticus Infection Control and Hospital Epidemiology, 10(9), 402-407.
37. Giamarellos-Bourboulis E.J., Xirouchaki. E., Giamarellou H. (2001). Interactions of colistin and rifampin on multidrug-resistant Acinetobacter baumannii Diagnostic Microbiology and Infectious Disease 40, 117-120.
38. Giamarellou H., Antoniadou A., Kanellakopoulou K. (2008). Acinetobacter baumannii: a universal threat to public health? International Journal of Antimicrobial Agents 32, 106-119
39. Gordon N.C., Wareham. D. W. (2009). A review of clinical and microbiological outcomes following treatment of infections involving multidrug-resistant Acinetobacter baumannii with tigecycline Journal of Antimicrobial Chemotherapy, 63, 775-780.
40. Gradon J.D., Chapnick. E. K., Lutwick L. I. (1992). Infective endocarditis of a native valve due to Acinetobacter: Case report and review Clinical Infectious Diseases, 14(5), 1145-1148.
41. Grotiuz G., Sirok. A., Gadea P., & other authors (2006). Shiga toxin 2-producing Acinetobacter haemolyticus associated with a case of bloody diarrhea Journal of Clinical Microbiology,44(10),3838-3841.
42. Haddad F.A., Van Horn.K., Carbonaro C., & other authors (2005). Evaluation of antibiotic combinations against multidrug-resistant Acinetobacter baumannii using the E-test. European Journal of Clinical Microbiology and Infectious Diseases 24(577), 577-579.
43. Hogg G. M., Barr J. G. a. Webb. C. H. (1998). In-vitro activity of the combination of colistin and rifampicin against multidrug-resistant strains of Acinetobacter baumannii Journal of Antimicrobial Chemotherapy41,494-496
44. Ikonomidis A., Pournaras S., Maniatis A.N. (2006). Discordance of meropenem versus imipenem activity against Acineto-bacter baumannii. International Journal of Antimicrobial Agents 28, 374-378.
45. Jiménez-Mejías M.E., Pachón J., Becerril B., & other authors (1997). Treatment of multidrug- resistant Acinetobacter bauma-nnii meningitis with Ampicillin/ Sulbac-tam Clinical Infectious Diseases, 24(5), 932-935.
46. Johnson E. N., Burns T. C., Hayda R.A., & other authors (2007). Infectious complications of open type III tibial fractures among combat casualties Clinical Infectious Diseases, 45, 409-415.
47. Joly-Guillou M.L. (2005). Clinical impact and pathogenicity of Acinetobacter. Clinical Microbiology And Infection, 11, 868-873.
48. Jones R.N., Sader H. S., Fritsche T.R., Rhomberg P.R. (2006). Carbapenem Susceptibility Discords among Acinetobacter Isolates. Clinical Infectious Diseases 42, 158.
49. Kallel H., Bahloul M., Hergafi L., & other authors (2006). Colistin as a salvage therapy for nosocomial infections caused by multidrug-resistant bacteria in the ICU International Journal of Antimic-robial Agents, 28, 366-369.
50. Karageorgopoulos D. E., Falagas. M. E. (2008). Current control and treatment of multidrug- resistant Acinetobacter baumannii infections Lancet Infectious Diseases 8, 751-762.
51. Kau H., Tsai C., Kao S., & other authors (2002). Corneal ulcer of the side port after phacoemulsification induced by Acine-tobacter baumannii. Journal of Cata-ract and Refractive Surgery, 28, 895-897.
52. Kim M., Peleg A. Y., Lodise T.P., & other authors (2009). Management of meningitis due to antibiotic-resistant Acinetobacter species. Lancet Infectious Diseases 9, 245-255.
53. Klastersky J., Zinner S. H. (1982). Synergistic combinations of antibiotics in Gram-negative bacillary infections. Revi-ews of Infectious Diseases, 4(2), 294-301.
54. Ko K.S., Yoeun Suh J., Tae Kwon K., & other authors (2007). High rates of resistance to colistin and polymyxin B in subgroups of Acinetobacter baumannii isolates from Korea Journal of Antimicro-bial Chemotherapy 60, 1163-1167.
55. Kocazeybek B.K., Arabaci U., Erenturk S., Akdur H. (2002). Investigation of various antibiotic combinations using the E-test method in multiresistant Pseudom-onas aeruginosa strains. Chemotherapy 48, 31-35.
56. Krcmery V., Demitrovicova A., Hricak V., Kisac P. (2010). Endocarditis due to Gram-negative bacteria. International Journal of Infectious Diseases, 2010(1), 1.
57. La Scola B., Raoult D. (2004). Acinetobacter baumannii in human body Louse Emerging Infectious Diseases, September, 10 (9), 1671-1673.
58. Leung W., Chu C., Tsang K., & other authors (2006). Fulminant community- acquired Acinetobacter baummannii pneumonia as a distinct clinical syndrome. Chest, 129, 102-108
59. Levin A.S., Levy C. E., Edison A., & other authors (2003). Severe nosocomial infections with imipenem-resistant Acinetobacter baumannii treated with ampicillin/sulbactam International Journal of Antimicrobial Agents 21, 58-62.
60. Lewis R.E., Diekema D.J., Messer S.A., & other authors (2002). Comparison of E-test, chequerboard dilution and time-kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species. Journal of Antimicrobial Chemotherapy 49, 345-351.
61. Li J., Rayner C. R., Nation R. L., & other authors (2006). Heteroresistance to colistin in multidrug-resistant Acinetobacter baumannii. Antimicrobial Agents and Chemotherapy,50(9), 2946-2950
62. Lortholary O., Fagon. J., Hoi A.B., & other authors (1995). Nosocomial acquisition of multiresistant Acinetobacter baumannii: risk factors and prognosis. Clinical Infectious Diseases, 20(4), 790-796.
63. Lu C., Chang W., Chuang Y., Chang H. (1999). Gram-negative bacillary menin-gitis in adult post- neurosurgical patients. Surgical Neurology 439(52), 438-444.
64. Manikal V.M., Landman D., Saurina G., & other authors (2000). Endemic carbapenem-resistant Acinetobacter species in Brooklyn, New York: citywide prevalence, Interinstitutional spread, and relation to antibiotic usage. Clinical Infectious Diseases 31, 101-106.
65. Manno G., Ugolotti E., Belli M. L., & other authors (2003). Use of the E test to Assess Synergy of Antibiotic Combinations Against Isolates of Burkholderia cepacia-Complex from Patients with Cystic Fibrosis. European Journal of Clinical Microbiology and Infectious Diseases 22,28-34.
66. Maragakis L.L., Perl T. M. (2008). Acinetobacter baumannii: epidemiology, antimicrobial resistance and treatment options. Clinical Infectious Diseases 46, 1254-1263.
67. Matthaiou D.K., Michalopoulos A., Rafailidis P.I., & other authors (2008). Risk factors associated with the isolation of colistin-resistant Gram-negative bacteria: A matched case- control study. Critial Care Medicine 36(3), 807-811.
68. McDonald L.C., Banerjee S. N., Jarvis W.R. (1999). Seasonal Variation of Acinetobacter Infections: 1987–1996. Clinical Infectious Diseases 29,1133-1137.
69. Moellering R.C., (1979). Antimicrobial Synergism: An Elusive Concept. Journal of Infectious Diseases, 140(4), 639-641.
70. Montero A., Ariza J., Corbella X., & other authors (2004). Antibiotic combinations for serious infections caused by carbapenem-resistant Acinetobacter baumannii in a mouse pneumonia model Journal of Antimicrobial Chemotherapy 54, 1085-1091.
71. Murray C.K. (2006). Bacteriology of war wounds at the time of injuryMilitary Medicine, 171(9), 826-829.
72. Navon-Venezia S., Leavitt A., Carmeli Y. (2007). High tigecycline resistance in multidrug- resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 59, 772-774.
73. Norden C.W., Wentzel H., Keleti E. (1979). Comparison of techniques for measurement of in vitro antibiotic synergism. Journal of Infectious Diseases, 140(4), 629-633
74. Olut A.I., Erkek E. (2005). Early prosthetic valve endocarditis due to Acinetobacter baumannii: A case report and brief review of the literature. Scandinavian Journal of Infectious Diseases,1, 919-921
75. Oncul O., Keskin O., Acar H.V., & other authors (2002). Hospital-acquired infections following the 1999 Marmara earthquake. Journal of Hospital Infection, 51, 47-51.
76. Pachon-Ibanez M.E., Fernandez-Cuenca C. F.,Docobo-Perez F.,& other authors(2006).Prevention of rifampicin resistance in Acinetobacter baumannii in an experimental pneumonia murine model, using rifampicin associated with imipenem or sulbactam. Journal of Antimicrobial Chemotherapy 58, 689-692.
77. Pantopoulou A., Giamarellos-Bourboulis. E. J., Raftogannis M., & other authors (2007).
78. Colistin offers prolonged survival in experimental infection by multidrug-resistant Acinetobacter baumannii: the significance of co-administration of rifampicin. International Journal ofAntimicrobial Agents 29, 51-55.
79. Paolino K., Erwin D., Padharia V., & other authors (2007). In vitro activity of colistin against multidrug-resistant Gram-negative bacteria isolated at a major Army hospital during the military campaigns in Iraq and Afghanistan. Clinical Infectious Diseases, 45, 140-141.
80. Park Y.K., Jung S., Park K., & other authors (2009). Independent emergence of colistin- resistant Acinetobacter spp. isolates from Korea. Diagnostic Microbi-ology and Infectious Disease 64, 43-51.
81. Peleg A.Y., Seifert H., Paterson D.L. (2008). Acinetobacter baumannii: Emerg-ence of a successful pathogen. Clinical Microbiology Reviews 21(3), 538-582.
82. Peleg A.Y., Potoski B. A., Rea R., & other authors (2007). Acinetobacter baumannii bloodstream infection while receiving tigecycline: a cautionary report. Journal of Antimicrobial Chemotherapy, 59, 128-131.
83. Petersen K, Riddle M. S., Danko J.R., & other authors (2007). Trauma-related Infections in Battlefield Casualties From Iraq. Annals of Surgery, 245(5), 803–811.
84. Principe L., D'Arezzo S., Capone A., Petrosillo N., Visca P. (2009). In vitro activity of tigecycline in combination with various antimicrobials against multidrug resistant Acinetobacter baumannii. Annals of Clinical Microbiology and Antimicrobials 8(18), 1-10.
85. Rhomberg P.R., Jones R. N. (2003). Antimicrobial spectrum of activity for meropenem and nine broad spectrum antimicrobials: report from the MYSTIC Program (2002) in North America. Diagnostic Microbiology and Infectious Disease 47, 365-372.
86. Rodriguez-Baño J., Cisneros J. M., Fernández-Cuenca F.R. & other authors (2004). Clinical features and epidemiology of Acinetobacter baumannii colonization and infection in Spanish hospitals Infection Control and Hospital Epidemiology, 25(10), 819-824.
87. Saballs M, Pujol. M., Tubau F, & other authors (2006). Rifampicin/imipenem combination in the treatment of carbap-enem resistant Acinetobacter bauma-nnii infections. Journal of Antimic-robial Chemotherapy,58,697-70090.
88. Schwalbe R., Steele-Moore L., Goodwin A.C. (Ed.). (2007). Antimicrobial Susceptibility Testing Protocols. New York: CRC Press.
89. Scott P., Deye G., Srinivasan A., & other authors (2007). An outbreak of multidrug-resistant Acinetobacter baumannii-calcoaceticus Complex infection in the US Military health care system associated with military operations in Iraq. Clinical Infectious Diseases 44, 1577-1584.
90. Seifert H., Dijkshoorn L., Gerner-smidt P., & other authors (1997). Distribution of Acinetobacter Species on Human Skin: Comparison of Phenotypic and Genotypic Identification Methods Journal of Clinical Microbiology 35(11), 2819-2825.
91. Sherertz R.J., Sullivan M. L. (1985). An Outbreak of Infections with Acinetobacter calcoaceticus in Burn Patients: Contamination of patients' mattresses. Journal of Infectious Diseases,151(2), 252-258.
92. 90.Siegman-IgraY,Bar-Yosef S.,GoreaA., Avram J.(1993).Nosocomial Acinetobacter meningitis secondary to invasive procedures: Report of 25 cases and review. Clinical Infectious Diseases 17(5), 843-849.
93. Smolyakov R., Borer A., Riesenberg K., & other authors (2003). Nosocomial multi-drug resistant Acinetobacter baumannii bloodstream infection: risk factors and outcome with ampicillin-sulbactam treatment. Journal of Hospital Infection 54, 32-38.
94. Song J. Y., Cheong H. J., Lee J., & other authors (2009). Efficacy of monotherapy and combined antibiotic therapy for carbapenem-resistant Acinetobacter baumannii pneumonia in an immunosuppressed mouse model. International Journal of Antimicrobial Agents 33, 33-39.
95. Song J.Y., Lee J., Heo J. Y., & other authors (2008). Colistin and rifampicin combination in the treatment of ventilator-associated pneumonia caused by carbapenem resistant Acinetobacter baumannii. International Journal of Antimicrobial Agents 32, 281-283.
96. Souli M., Rekatsina. P.D., Chryssouli Z., & other authors (2009). Does the activity of the combination of imipenem and colistin in vitro exceed the problem of resistance in metallo-ß- lactamase-producing Klebsiella pneumoniae isolates? Antimicrobial Agents And Chemotherapy, 53(5), 2133-2135.
97. Starakis I., Blikas A., Siagris D., & other authors (2006). Prosthetic valve endocarditis caused by Acinetobacter lwoffii. A case report and review. Cardiology in Review 14, 45-49.
98. 96.Swenson J. M., Killgore G. E., Tenover F.C. (2004). Antimicrobial susceptibility testing of Acinetobacter spp. by NCCLS broth microdilution and disk diffusion methods. Journal of Clinical Microbiology, 42(11), 5102-5108.
99. Thamlikitkul V., Tiengrim S., Tribuddharat C. (2007). Comment on: high tigecycline resistance in multidrug-resistant Acinetobacter baumannii. Journal of Antimicrobial Chemotherapy 10, 177-178.
100. Thornsberry C., Hill. B. C., Swenson J.M., McDougal L.K. (1983). Rifampin: Spectrum of Antibacterial Activity. Reviews of Infectious Diseases, 5, Supplement 3, S412-S417.
101. Timurkaynak F., Can F., Azap O.K., & other authors (2006). In vitro activities of non-traditional antimicrobials alone or in combination against multidrug-resistant strains of Pseudomona aeruginosa and Acinetobacter baumannii isolated from intensive care units. International Journal of Antimicrobial Agents 27, 224-228.
102. Towner K.J. (2009). Acinetobacter: an old friend, but a new enemy. Journal of Hospital Infection73, 355-363.
103. Tripodi M., Durante-Mangoni E., Fortunato R., & other authors (2007). Comparative activities of colistin, rifampicin, imipenem and sulbactam/ ampicillin alone or in combination against epidemic multidrug-resistant Acinetobacter baumannii isolate producing OXA-58 carbapenemases. International Journal of Antimicrobial Agents 30, 537-540.
104. Rahul kamble and other authors (2015). Acinetobacter species in health care setting : clinical significance and antimicrobial sensitivity. International journal of current microbiology and applied sciences,volume 4 page no 861-869.
105. Deveshni Reddy & other authors (2014).Acinetobacter Baumannii Infections in Paediatric ICU of a tertiary hospital in south Africa:RDDV04
106. Namita jaggi & other authors (2012). Acinetobacter isolates intertiary health care setting : clinical significance and antimicrobial sensitivity. Journal of microbiology and current disease ,volume 2 page no 57-63.
107. R.B. Patwardhan, P.K. Dhakephalkar & Authors(2008):A study on nosocomial pathogens in ICU with special reference to multiresistant Acinetobacter baumannii harbouring multiple plasmids;Indian j med res page no 178-187.
108. B N Chaudhuri , V balaji , R iyer & U Shekhar & Authors(2011):Incidence of ESBL Producers amongst Gram-negativeBacilli Isolated from Intra-abdominal Infections across India (Based on SMART Study, 2007 Data)the journal of association of india
109. Azinun Nahar ,Saheda Anwar & Authors(2012):Isolation of acinetoacter and their antimicrobial resistence pattern in an ICU of a tertiary care hospital in Dhaka,Bangladesh.BJMM;06(01):03-06.
110. Ali faisal saleem ,Imran ahmed & Authors(2010):Pan-resistant Acinetobacter infection in neonates in Karachi,Pakistan: J Infect Dev Ctries 2010;4(1):030-037.
